RxDoctor Payments Data

Kashif Aslam, MD

Critical Care Medicine · Mansfield, TXNPI 1548432636

Payments from drug & device makers

$6,843in general payments, 2019–2025

Across 80 payments — averaging $85.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Pinnacle Biologics, Inc$2K
  • Johnson & Johnson$985
  • Inspire Medical Systems, Inc.$187
  • AstraZeneca$166
  • Abiomed$151
  • plus $550 from 12 others

What the payments were for

  • Speaking & faculty fees$1,00015%
  • Travel & lodging$4,01359%
  • Food & beverage$1,65524%
  • Gifts$1753%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,843 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$124,994
Medicare patients
326
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$34,195
Breo ElliptaFluticasone/Vilanterol24$9,212
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,278
SymbicortBudesonide/Formoterol Fumarate11$4,260
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,018
Albuterol Sulfate HfaAlbuterol Sulfate78$1,483
Wixela InhubFluticasone Propion/Salmeterol13$830
Levalbuterol Tartrate HfaLevalbuterol Tartrate13$767
Montelukast Sodium28$306
Fluticasone Propionate13$212
Azithromycin11$72
Prednisone27$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$68$50,68487 claims
AstraZenecaSymbicort$166$4,26011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →